Schemes & Policies

Delhi HC Refuses Stay on Gardasil HPV Vaccination for 14-Year-Old Girls

30 July 2026UPSCSSCBank

In Brief

Delhi High Court upholds Centre's national drive deploying HPV vaccine Gardasil for adolescent girls.

The Delhi High Court declined to grant an interim stay on the administration of the Human Papillomavirus (HPV) vaccine Gardasil to 14-year-old girls under the Central Government's nationwide immunization program. The court observed that public health initiatives aimed at preventive oncology carry strong scientific backing and public interest benefits.

The legal challenge raised concerns over potential adverse side effects and informed consent protocols regarding mass Gardasil administration. However, the bench noted that the vaccine had undergone extensive clinical trials and received clearance from the Drugs Controller General of India (DCGI) and technical advisory bodies.

Cervical cancer ranks as the second most common cancer among women in India, accounting for nearly 1.2 lakh new cases and over 75,000 deaths annually. The HPV vaccine targets high-risk strains (primarily HPV 16 and 18) responsible for over 70 percent of cervical cancer cases, with the Centre aiming for target coverage under Universal Immunization guidelines.

This judgment is important for Health, Public Policy, and Science & Technology (GS Paper II & III). Candidates should prepare details on cervical cancer etiology, DCGI approval mechanisms, National Technical Advisory Group on Immunization (NTAGI), and public health rights.

UPSC Study NotesHIGHGS2 — Social Justice (Health) & GS3 — Science & Technology

GS2 — Social Justice (Health) & GS3 — Science & Technology

📌 Exam Angle

Prelims may test HPV transmission, strains 16 and 18, and regulatory bodies like NTAGI and DCGI. Mains questions can probe how integrating preventive oncology into the Universal Immunization Programme addresses women’s health equity and reduces non-communicable disease burden.

⚠️ Key Concerns

Major challenges include handling public vaccine hesitancy, ensuring legal informed consent protocols for minors, and maintaining cold-chain logistics. The debate highlights the delicate balance between judicial deference to technical health bodies and protecting individual bodily autonomy.

💡 Why It Matters

With cervical cancer causing over 75,000 annual deaths in India, mass HPV vaccination transforms reactive healthcare into cost-effective preventive oncology. This ruling reinforces evidence-based policymaking, safeguarding public health over socio-legal friction.

🔑 Must Remember

• High-risk HPV strains 16 and 18 account for over 70% of Indian cervical cancer cases. • NTAGI evaluates scientific evidence to advise the Centre on national immunization policies. • CERVAVAC is India’s first indigenously developed quadrivalent HPV vaccine by Serum Institute.

📝 Key Terms

Cervical CancerHuman PapillomavirusGardasilCERVAVACNTAGIDCGIPreventive OncologyUniversal Immunization Programme

Delhi HC Refuses Stay on Gardasil HPV Vaccination for 14-Year-Old Girls

More in Schemes & Policies